Literature DB >> 6888193

Complete, reversible, drug-specific tolerance to stimulation of locomotor activity by caffeine.

S G Holtzman.   

Abstract

The development of tolerance to caffeine-induced stimulation of locomotor activity was evaluated in rats maintained chronically on average daily doses of 160 mg/kg or more of caffeine by the method of scheduled access to drinking water containing the drug. Dose-response curves were determined for caffeine (6.25-100 mg/kg) and d-amphetamine (0.39-6.4 mg/kg) during chronic drug treatment. In addition, the caffeine curve was redetermined 2-3 weeks after removal of the drug from the drinking water. A control group that had scheduled access to drug-free tap water was also tested. Caffeine produced dose-related increases in the locomotor activity of the controls but failed to modify locomotor activity of the chronic caffeine group. In contrast, d-amphetamine increased locomotor activity of both groups comparably. Spontaneous locomotor of the chronic caffeine group was reduced significantly for 4 days after drug-free tap water was substituted for the caffeine solution. The return of spontaneous locomotor activity to baseline values was associated with restored sensitivity to caffeine-induced stimulation of locomotor activity. Thus, chronic administration of caffeine to rats results in the development of tolerance to caffeine-induced stimulation of locomotor activity that is virtually complete, pharmacologically specific, and fully reversible when drug treatment is stopped. Decreases in spontaneous locomotor activity after abrupt termination of chronic caffeine administration follow a time course consistent with a drug withdrawal syndrome.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6888193     DOI: 10.1016/0024-3205(83)90784-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

1.  Adolescent caffeine consumption increases adulthood anxiety-related behavior and modifies neuroendocrine signaling.

Authors:  Casey E O'Neill; Ryan J Newsom; Jacob Stafford; Talia Scott; Solana Archuleta; Sophia C Levis; Robert L Spencer; Serge Campeau; Ryan K Bachtell
Journal:  Psychoneuroendocrinology       Date:  2016-02-01       Impact factor: 4.905

2.  Evaluating Dependence Criteria for Caffeine.

Authors:  Catherine L W Striley; Roland R Griffiths; Linda B Cottler
Journal:  J Caffeine Res       Date:  2011-12

3.  The role of adenosine receptors in the central action of caffeine.

Authors:  John W Daly; Dan Shi; Olga Nikodijevic; Kenneth A Jacobson
Journal:  Pharmacopsychoecologia       Date:  1994

4.  Changes in caffeine seizure threshold after electroconvulsive shock.

Authors:  C H Gleiter; J Deckert; D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 5.  Caffeine dependence: fact or fiction?

Authors:  E C Strain; R R Griffiths
Journal:  J R Soc Med       Date:  1995-08       Impact factor: 5.344

6.  Long-lasting tolerance to stimulatory effects of perinatal caffeine treatment.

Authors:  G Lombardelli; W Balduini; A Feduzi; G Peruzzi; F Cattabeni
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Effects of adolescent caffeine consumption on cocaine self-administration and reinstatement of cocaine seeking.

Authors:  Tracey A Larson; Casey E O'Neill; Michaela P Palumbo; Ryan K Bachtell
Journal:  J Psychopharmacol       Date:  2018-11-28       Impact factor: 4.153

Review 8.  Caffeine physical dependence: a review of human and laboratory animal studies.

Authors:  R R Griffiths; P P Woodson
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 9.  Psychostimulants and cognition: a continuum of behavioral and cognitive activation.

Authors:  Suzanne Wood; Jennifer R Sage; Tristan Shuman; Stephan G Anagnostaras
Journal:  Pharmacol Rev       Date:  2013-12-16       Impact factor: 25.468

10.  Pharmacologic specificity of tolerance to caffeine-induced stimulation of locomotor activity.

Authors:  I B Finn; S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.